Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function
- 115 Downloads
Prescription of non-vitamin K antagonist oral anticoagulants (NOACs) requires an assessment of renal function (RF) and the Cockcroft–Gault (CG) equation is traditionally recommended. The objective of the study was to evaluate the potential changes in NOACs management using different equations for estimating RF. In a post hoc analysis of a prospective cohort of patients with atrial fibrillation, we considered different equations: (1) CG for creatinine clearance (CrCl), (2) modification of diet in renal disease (MDRD), (3) CKD-EPI, (4) Berlin Initiative Study 1 (BIS-1) and (5) full age spectrum (FAS), for glomerular filtration rate (GFR). RF was classified according to CrCl in three categories: severely depressed (SD-RF) < 30 ml/min; moderately depressed (MD-RF) 30–49 ml/min; preserved/mildly depressed (P-RF) ≥ 50 ml/min. Concordances in the assignments were analyzed. A population of 402 patients (61.2% males, age 72 ± 11) was categorized according to CrCl: 12 patients (2.9%) as SD-RF, 81 (20.1%) as MD-RF, 309 (76.8%) as P-RF. A potential change in NOACs management could occur using GFR equations rather than CrCl in 16.9% of patients using MDRD formula, in 11.7% using BIS-1, in 14.7% using CKD-EPI and in 12.9% using the FAS equation. Important changes in RF estimates were more frequent in patients aged ≥ 75, but also BMI had a meaningful impact. Use of equations estimating GFR instead of the Cockcroft–Gault equation may result in changes in NOACs management in 12–17% of patients. In the elderly ≥ 75, more pronounced changes in RF classification are detectable according to different equations and NOACs dosing should be further investigated.
KeywordsAnticoagulation Atrial fibrillation Non-vitamin K antagonists oral anticoagulants Renal function Glomerular filtration rate Creatinine clearance
Compliance with ethical standards
Conflict of interest
Statements on human and animal rights
The study had been approved by the appropriate institutional research ethics committee. All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC), Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, endorsed by the European Stroke Organisation. Eur Heart JGoogle Scholar
- 9.Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747CrossRefGoogle Scholar
- 13.(2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international 3:1–150Google Scholar
- 14.Lip GYH, Collet JP, Caterina R et al (2017) Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 19:1757–1758CrossRefGoogle Scholar
- 21.Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360–363Google Scholar
- 23.(1998) Food and Drug Administration: guidance for industry: pharmacokinetics in patients with impaired renal function— study design, data analysis, and impact on dosing and labeling. Department of Health and Human Services, Rockville, May. https://www.fda.gov/downloads/drugs/guidances/ucm204959.pdf
- 27.Boriani G, Savelieva I, Dan GA et al (2015) Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 17:1169–1196CrossRefGoogle Scholar
- 28.January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–76CrossRefGoogle Scholar
- 35.NKDEP (2010) NKDEP. National Kidney Disease Education Program. Chronic kidney disease and drug dosing: information for providers. http://www.nkdep.nih.gov/professionals/CKD_DrugDosing_508.pdf
- 36.(2010) US Food and Drug Administration (2010). Draft guidance for industry: pharmacokinetics in patient with impaired kidney function—study design DA, and impact on dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf